Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]

Fei Y, Xie Z, Luo Y, et al. Drug Des Devel Ther. 2025;19:3751–3761. Page 3760, first line, the text “Our current study had similar findings” should read “Our study observed an increase in the exposure to HRS-1780 with both mild and moderat...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Y, Xie Z, Luo Y, Yong X, Li N, Huang R, Du X, Zhu Y, Lan D, Qi Y, Cheng G, Wang Q, Shen K
Format: Article
Language:English
Published: Dove Medical Press 2025-06-01
Series:Drug Design, Development and Therapy
Subjects:
mineralocorticoid receptor antagonist
pharmacokinetics
renal impairment
chronic kidney disease
Online Access:https://www.dovepress.com/corrigendum-pharmacokinetics-and-safety-of-hrs-1780-in-renal-impaired--peer-reviewed-fulltext-article-DDDT
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/corrigendum-pharmacokinetics-and-safety-of-hrs-1780-in-renal-impaired--peer-reviewed-fulltext-article-DDDT

Similar Items